T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine

Vaccine

Volumn 23, Issue 19, 2005, Pages 2439-2453

  Haas, Claudia ^a   Lulei, Maria ^a   Fournier, Philippe ^a   Arnold, Annette ^a   Schirrmacher, Volker ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Bispecific single chain antibody; CD3 and CD28 cross linking; Newcastle Disease Virus

Indexed keywords

BISPECIFIC ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; CD69 ANTIGEN; CHEMOKINE; CYTOKINE; HN PROTEIN; INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; NEWCASTLE DISEASE VACCINE; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR CELL VACCINE; VIRUS SIALIDASE; ANTIBODY; CANCER VACCINE; INTERLEUKIN 2 RECEPTOR; LEUKOCYTE ANTIGEN; LYMPHOKINE; T LYMPHOCYTE ANTIGEN; VIRUS ANTIGEN;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS LINKING; CYTOKINE RELEASE; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR CELL; TUMOR IMMUNITY; UPREGULATION; VIRUS; ANIMAL; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIGENS, VIRAL; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HN PROTEIN; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE ACTIVATION; LYMPHOKINES; MICE; NEWCASTLE DISEASE VIRUS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 14744287614     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.10.031     Document Type: Article

References (53)

1. O. Acuto, and R. Michel CD28-mediated co-stimulation: a quantitative support for TCR signalling Nat Rev Immunol 3 2003 939 950
2. A.H. Sharpe, and G.J. Freeman The B7-CD28 superfamily Nat Rev Immunol 2 2002 2116 2126
3. P. Matzinger The danger model: a renewed sense of self Science 296 2002 301 305
4. P.J. Noel, L.H. Boise, J.M. Green, and C.B. Thompson CD28 co-stimulation prevents cell death during primary T cell activation J Immunol 157 1996 636 642
5. P.J. Lucas, I. Negishi, K. Nakayama, I.E. Fields, and D.Y. Loh Naïve CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response J Immunol 154 1995 5757 5768
6. V.L. Perez, L. Van Parijis, A. Biuckians, X.X. Zheng, T.B. Strom, and A.K. Abbas Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement Immunity 6 1997 411 417
7. L Immunity 3 1995 87 98
8. J.A. Nunès, Y. Collette, A. Truneh, D. Olive, and D.A. Cantrell The role of p21ras in CD28 signal transduction triggering of CD28 with antibodies but not the ligand B7-1, activates p21ras J Exp Med 180 1994 1067 1076
9. V. Schirrmacher, C. Haas, R. Bonifer, T. Ahlert, R. Gerhards, and C. Ertel Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle Disease Virus Gene Ther 6 1999 63 73
10. B. Washburn, and V. Schirrmacher Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis Int J Oncol 21 2002 85 93
11. J. Zeng, P. Fournier, and V. Schirrmacher Induction of interferon α and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle Disease Virus Virology 297 2002 19 30
12. P. Fournier, J. Zeng, and V. Schirrmacher Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-α responses by viral protein or dsRNA Int J Oncol 23 2003 673 680
13. L. Alexopoulou, A.C. Holt, R. Medzhitov, and R.A. Flavell Recognition of double-stranded RNA and activation of NF-k B by Toll-like receptor 3 Nature 413 2001 732 738
14. T. Ahlert, and V. Schirrmacher Tumor cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines J Clin Oncol 15 1997 1354 1366
15. A. Traunecker, A. Lanzavecchia, and K. Karjalainen Bispecific single-chain molecules (Janusins) target cytotoxic lymphocytes on HIV-infected cells EMBO J 10 1991 3655 3659
16. P.S. Linsley, W. Brady, L. Grosmaire, A. Aruffo, N.K. Damle, and J.A. Ledbetter Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation J Exp Med 173 3 1991 721 730
17. R.M. Iorio, R.L. Glickman, A.M. Riel, J.P. Sheehan, and M.A. Bratt Functional and neutralization profile of seven overlapping antigenic sites on the HN glycoprotein of Newcastle Disease Virus: monoclonal antibodies to some sites prevent viral attachment Virus Res 13 1989 245 261
18. N.K. Damle, J.A. Hansen, R.A. Good, and S. Gupta Monoclonal antibody analysis of human T lymphocyte subpopulations exhibiting autologous mixed lymphocyte reaction Proc Natl Acad Sci USA 78 8 1981 5096 5098
19. A. Auerswald, R. Morenweiser, C.P. Sommerhoff, G.P. Piechottka, C. Eckerskorn, and L.G. Gürtler Recombinant leech-derived tryptase inhibitor: construction, production, protein chemical characterization and inhibition of HIV-1 replication Biol Chem Hoppe-Seyler 375 1994 695 703
20. J. Sambrook, E.F. Fritsch, and T. Maniatis Molecular cloning: a laboratory manual 2nd ed. 1989 Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY
21. P. Von Hoegen, R. Zawatzky, and V. Schirrmacher Modification of tumor cells by a low dose of Newcastle Disease Virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon αβ Cell Immunol 126 1990 80 90
22. C. Ertel, N.S. Millar, P.T. Emmerson, V. Schirrmacher, and P. von Hoegen Viral hemagglutinin augments peptide-specific cytotoxic T cell responses Eur J Immunol 23 1993 2592 2596
23. C. Haas, C. Herold-Mende, R. Gerhards, and V. Schirrmacher An effective strategy of human tumor vaccine modification by coupling bispecific co-stimulatory molecules Cancer Gene Ther 6 3 1999 254 262
24. M. Mack, G. Riethmüller, and P.A. Kufer Small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity Proc Natl Acad Sci USA 92 1995 7021 7025
25. L. Chen, S. Ashe, W.A. Brady, I. Hellstrom, K.E. Hellstrom, and J.A. Ledbetter Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 71 1992 1093 1102
26. J.A. Bluestone New perspectives of CD28-B7 mediated T-cell costimulation Immunity 2 1995 555 559
27. R.S. McHugh, S.N. Ahmed, Y.C. Wang, K.W. Sell, and P. Selvaraj Construction, purification and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80) Proc Natl Acad Sci USA 92 1995 8059 8063
28. P. Kufer, F. Zettl, K. Borschert, R. Lutterbuse, R. Kischel, and G. Riethmüller Minimal costimulatory requirements for T cell priming and TH1 differentiation: Activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs Cancer Immun 1 2001 1 22
29. A.Y. Huang, A.T. Bruce, D.M. Pardoll, and H.I. Levitsky Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 183 1996 769 776
30. C.C. Termeer, V. Schirrmacher, E.B. Brocker, and J.C. Becker Newcastle Disease Virus infection induces a B7-1/B7-2 independent T cell-costimulatory activity in human melanoma cells Cancer Gene Ther 7 2000 316 323
31. + peripheral blood T lymphocytes of patients with melanoma Clin Cancer Res 7 2001 947s.
32. - T cells have signalling defects in patients with squamous cell carcinoma of the head and neck Br J Cancer 88 2003 223 230
33. M. Feuerer, P. Beckhove, L. Bai, E.F. Solomayer, G. Bastert, and I.J. Diel Therapy of human tumors in NOD/SCID mice with patient derived re-activated memory T cells from bone marrow Nat Med 7 2001 452 458
34. S.A. Möller, and R.A. Reisfeldt Bispecific-monoclonal-antibody- directed lysis of ovarian carcinoma cells by activated human T-lymphocytes Cancer Immunol Immunother 33 1991 210 216
35. C. Renner, W. Jung, R. van Lier, U. Sahin, and M. Pfreundschuh The role of lymphocyte subsets and adhesion molecules in T-cell dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies Eur J Immunol 25 1995 2027 2033
36. B.J. Kroesen, A. Bakker, R.W. van Lier, H.T. The, and L. de Leij Bispecific antibody-mediated target cell-specific costimulation of resting T-cells via CD5 and CD28 Cancer Res 55 1995 4409 4415
37. C. Haas, G. Strauß, G. Moldenhauer, R.M. Iorio, and V. Schirrmacher Bispecific antibodies increase T cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine Clin Canc Res 4 1998 721 730
38. P. Kufer, M. Mack, R. Gruber, R. Lutterbuse, F. Zettl, and G. Riethmuller Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer Cancer Immunol Immunother 45 1997 193 197
39. T. Dreier, G. Lroenczewski, C. Brandl, P. Hoffmann, U. Syring, and F. Hanakam Exptremely potent, rapid and costimulation-independent cytotoxic T cell response against lymphoma cells catalyzed by a single-chain bispecific antibody Int J Cancer 100 2002 690 697
40. L.P. Song, J.L. Cheng, X.B. Wang, Z. Zhang, M. Fang, and Z.Y. Zhou A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells Acta Biochim et Biophys Sin 35 2003 503 510
41. G.J. Weiner, S.A. Kostelny, J.R. Hillstrom, M.S. Cole, B.K. Link, and S.L. Wang The role of T cell activation in anti-CD3x anti-tumor bispecific antibody therapy J Immunol 152 1994 2385 2392
42. A. Löffler, P. Kufer, R. Lutterbüse, F. Zettl, P.T. Daniel, and J.M. Schwenkenbecher A recombinant bispecific single-chain antibody, CD19x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes Blood 95 2000 2098 2103
43. N. Jacobs, A. Mazzoni, D. Mezzanzanica, Negri DRM, O. Valota, and M.I. Colnaghi Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation Cancer Immunol Immunother 44 1997 257 264
44. + T cells through transfer of the peptide to T cell MHC molecules Proc Natl Acad Sci USA 99 2002 13729 13734
45. J.B. Huppa, and M.M. Davis T-cell antigen recognition and the immunological synapse Nature Rev Immunol 3 2003 973 983
46. M. van den Broek, D. Kagi, F. Ossendorp, R. Toes, S. Vamvakas, and W.K. Lutz Decreased tumor surveillance in perforin-deficient mice J Exp Med 184 1996 1781 1790
47. C.A. Chambers, M.S. Kuhns, J.G. Egen, and J.P. Allison CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy Annu Rev Immunol 19 2001 565 594
48. L. Ardouin, M. Bracke, A. Mathiot, S.N. Pagakis, T. Norton, and N. Hogg Vav1 transduces TCR signals required for LFA-1 function and cell polarization at the immunological synapse Eur J Immunol 33 2003 790 797
49. S. Kirchhoff, W.W. Muller, M. Li-Weber, and P.H. Krammer Up-regulation of c-FLIP short and reduction of activation-induced cell death in CD28-costimulated human T cells Eur J Immunol 30 2000 2765
50. A.L. Pecora, N. Rizvi, G.I. Cohen, N.I. Meropol, D. Sterman, and I.L. Marshall Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers J Clin Oncol 20 2002 2251 2266
51. J.M. Curtsinger, and D.C. Lins Mescher MF. Signal 3 determines tolerance versus full activation of naïve CD8 T cells. Dissociating proliferation and development of effector function J Exp Med 197 2003 1141 1151
52. + T cells stimulated by virus-induced type I interferon Nat Immunol 4 2003 1009 1015
53. J. Vilcek Boosting p53 with interferon and viruses Nat Immunol 4 2003 825 826